Novel BiTE Molecule Shows Promise in Cancer Therapy

Strategic Insights -

In a collaborative research effort between MedImmune, Inc. and Micromet, Inc., a novel BiTE molecule, bscEphA2xCD3, has been developed to target the tyrosine kinase receptor EphA2, which is frequently overexpressed on solid tumors. This innovative compound has shown significant potential in in vitro studies, killing tumor cells at low nanogram/ml concentrations, and in mouse studies, redirecting unstimulated human T cells to inhibit human tumor outgrowth. The BiTE molecule's ability to selectively target cancer cells overexpressing EphA2 while sparing normal cells has sparked interest in its potential as a therapeutic agent in cancer treatment.

Key Takeaways:

  • The BiTE molecule, bscEphA2xCD3, targets the tyrosine kinase receptor EphA2, which is frequently overexpressed on solid tumors.
  • In vitro studies demonstrated bscEphA2xCD3's ability to kill tumor cells at low nanogram/ml concentrations, significantly below those required by classical monoclonal antibody-based therapies.
  • Mouse studies showed that the BiTE compound redirected unstimulated human T cells to inhibit human tumor outgrowth without the need for co-stimulation.
  • bscEphA2xCD3 triggered T cells to attack single tumor cells overexpressing EphA2 while sparing normal cells where the tyrosine kinase is sequestered within intercellular boundaries.
  • This novel BiTE molecule may have the potential to selectively direct and activate an individual's own immune system to act against cancer cells.
  • MedImmune holds the rights to bscEphA2xCD3, while Micromet is entitled to receive milestones and royalties in case of successful development and commercialization.
  • Micromet and MedImmune collaborate on the development of MT103/MEDI-538, a BiTE molecule targetting the CD19 antigen present on B cells.
  • MT103/MEDI-538 is being developed to treat B-cell non-Hodgkin lymphoma.

Statistics:

  • bscEphA2xCD3 killed tumor cells at concentrations below 10 nanograms/ml in vitro.
  • Tumor cell lysis approached 100% even at low ratios of effector T cells to target cells.
  • The BiTE compound redirected unstimulated human T cells to inhibit human tumor outgrowth in mouse studies.

Sources:

  • Health & Medicine Week editors, "MedImmune and Micromet Develop Novel BiTE Molecule Targeting EphA2," October 18, 2006.
  • Health & Medicine Week editors, "Micromet and MedImmune Collaborate on B-cell Non-Hodgkin Lymphoma Treatment," October 18, 2006.